BostonGene Announces Two Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition

Presentations Highlight the Integral Role of Tumor Microenvironment Analysis in Determining Cellular Composition and Gene Expression for Patients with Follicular Lymphoma

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced that two abstracts were selected for poster presentations at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition. The all-virtual event will be held from December 5 – 8, 2020.

Details of the presentations are below:

Title: Integration and Iteration: Using Advanced, High-Content Imaging and Single-Cell Gene Expression Analysis to Uncover Unique Aspects of Follicular Lymphoma Biology
Session: 621: Lymphoma—Genetic/Epigenetic Biology: Poster I
Abstract Number: 1106
Date and Time: Saturday, December 5, 2020: 10:00 AM - 6:30 PM ET
Presenter: Andrea J. Radtke, PhD, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

Follicular lymphoma is an indolent B-cell lymphoma with remarkable heterogeneity in disease progression and trajectory; therefore, determining the cell intrinsic and extrinsic factors underlying this clinical heterogeneity is necessary to impact patient clinical outcomes. Using a multi-omics approach, including whole exome sequencing (WES) and bulk RNA-seq integrated with single-cell analyses such as scRNA-seq and multiparameter imaging, notable patient-specific cellular interactions and expression patterns were identified that may drive cancer patient survival. This integrated approach provides insights into both tumor biology and disease trajectory, which can ultimately benefit therapeutic strategies in follicular lymphoma.

Research conducted with the National Cancer Institute (NCI) and the National Institute of Allergy and Infectious Diseases (NIAID), both part of the National Institutes of Health (NIH).

Title: High Dimensional Tissue-based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles
Session: 622
Abstract Number: 1117
Date and Time: Saturday, December 5, 2020: 10:00 AM - 6:30 PM ET
Presenter: Jose C. Villasboas, MD, Mayo Clinic

Cells of the immune system play an important role in modulating the trajectory of lymphomas; therefore, understanding the composition and spatial distribution of immune cells within the tumor microenvironment (TME) is critical to improve clinical outcomes for patients. Analysis of a follicular lymphoma tumor section that used Co-Detection by Indexing (CODEX) multiplex immunofluorescence image processing identified unique cell subsets and specific spatial distribution of immune cells. These insights into the complex immune cell composition and architecture of the TME add to the prognostic value of the TME as a therapeutic target in follicular lymphoma.

Research conducted with Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Université Claude Bernard Lyon and the University of Iowa.

In addition to the poster presentations, the abstracts have been published online in the November supplemental issue of "Blood”.

For more information, please visit the 62nd ASH Annual Meeting and Exposition website at https://www.hematology.org/meetings/annual-meeting/abstracts.

About BostonGene Corporation

BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.